|  |



Gilead's bictegravir, lenacapavir tablet meets mark in phase 3

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment Biktarvy and its new ...


View article...


Top stories of the last 30 days